Eloxx Pharmaceuticals’ (ELOX) Buy Rating Reaffirmed at Canaccord Genuity

Canaccord Genuity restated their buy rating on shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) in a research report sent to investors on Wednesday, The Fly reports. They currently have a $17.00 price target on the stock, down from their previous price target of $20.00. The analysts noted that the move was a valuation call.

Separately, Zacks Investment Research upgraded shares of Eloxx Pharmaceuticals from a hold rating to a buy rating and set a $13.00 price target for the company in a report on Monday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $19.40.

ELOX traded down $0.09 during midday trading on Wednesday, reaching $11.11. 420 shares of the company’s stock were exchanged, compared to its average volume of 30,332. Eloxx Pharmaceuticals has a 1-year low of $9.12 and a 1-year high of $24.60.



Eloxx Pharmaceuticals (OTCMKTS:ELOX) last announced its earnings results on Thursday, May 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.08.

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA purchased a new stake in shares of Eloxx Pharmaceuticals during the first quarter worth about $55,000. Citigroup Inc. grew its holdings in shares of Eloxx Pharmaceuticals by 20.6% during the fourth quarter. Citigroup Inc. now owns 7,432 shares of the company’s stock worth $89,000 after buying an additional 1,269 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in shares of Eloxx Pharmaceuticals by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,172 shares of the company’s stock worth $122,000 after buying an additional 7,944 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Eloxx Pharmaceuticals by 226.0% during the fourth quarter. Bank of America Corp DE now owns 14,209 shares of the company’s stock worth $171,000 after buying an additional 9,851 shares in the last quarter. Finally, State of Wisconsin Investment Board grew its holdings in shares of Eloxx Pharmaceuticals by 29.5% during the first quarter. State of Wisconsin Investment Board now owns 28,100 shares of the company’s stock worth $321,000 after buying an additional 6,400 shares in the last quarter.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Featured Article: Different Types of Derivatives

The Fly

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.